Revenue Insights: Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc. Performance Compared

Pharma Giants' Revenue Race: Jazz vs. Ionis

__timestampIonis Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20142141610001172875000
Thursday, January 1, 20152837030001324803000
Friday, January 1, 20163466200001487973000
Sunday, January 1, 20175076660001618693000
Monday, January 1, 20185996740001890922000
Tuesday, January 1, 201911230000002161761000
Wednesday, January 1, 20207290000002363567000
Friday, January 1, 20218100000003094238000
Saturday, January 1, 20225870000003659374000
Sunday, January 1, 20237876470003834204000
Monday, January 1, 2024705138000
Loading chart...

Data in motion

Revenue Growth: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc. have showcased intriguing revenue trajectories over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has consistently outperformed Ionis, with revenues peaking at approximately $3.8 billion in 2023, marking a growth of over 200% from 2014. In contrast, Ionis Pharmaceuticals, while experiencing a significant rise, saw its revenue increase by nearly 270% during the same period, reaching around $788 million in 2023.

The year 2019 was pivotal for Ionis, with revenues surpassing the billion-dollar mark, a testament to its innovative drug pipeline. Meanwhile, Jazz Pharmaceuticals' strategic acquisitions and robust product portfolio have fueled its steady ascent. As the pharmaceutical industry evolves, these companies exemplify the dynamic shifts and growth potential within the sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025